Audit Trail Review in Pharmaceutical and Biopharmaceutical Industries
Data integrity has become one of the most heavily scrutinized areas in pharmaceutical and biopharmaceutical manufacturing. As companies move away from paper-based systems toward computerized systems such as LIMS, MES, ERP, and chromatography data systems (CDS), the audit trail has emerged as one of the most important — and most frequently cited — elements in regulatory inspections. FDA Warning Letters, EMA findings, and MHRA data integrity guidance consistently flag inadequate audit trail review as a systemic failure, often linked to broader concerns about data reliability across a facility.